Production (Stage)
IGC Pharma, Inc.
IGC
$0.3808
-$0.0342-8.24%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.40% | -37.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.40% | -37.62% | |||
| Cost of Revenue | 15.03% | -28.50% | |||
| Gross Profit | 48.08% | -47.47% | |||
| SG&A Expenses | -45.22% | 8.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.07% | -1.70% | |||
| Operating Income | 22.15% | -6.70% | |||
| Income Before Tax | 34.55% | -6.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.55% | -6.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.55% | -6.52% | |||
| EBIT | 22.15% | -6.70% | |||
| EBITDA | 24.00% | -6.56% | |||
| EPS Basic | 36.44% | -4.42% | |||
| Normalized Basic EPS | 31.97% | -4.26% | |||
| EPS Diluted | 36.44% | -4.42% | |||
| Normalized Diluted EPS | 31.97% | -4.26% | |||
| Average Basic Shares Outstanding | 2.52% | 2.14% | |||
| Average Diluted Shares Outstanding | 2.52% | 2.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||